A Phase II Study of DAB 389 IL-2, an Interleukin-2 Fusion Toxin, for Previously Treated Stage II, III, and IV Follicular Low-Grade Non-Hodgkin's Lymphoma

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven stage I, II, III, or IV low- or
intermediate-grade B-cell non-Hodgkin's lymphoma Small lymphocytic Follicular small
cleaved cell Follicular mixed cell Follicular large cell Marginal Diffuse large B-cell
Lymphoplasmacytoid Patients with small lymphocytic lymphoma must have an absolute
lymphocyte count less than 10,000/mm3 At least one bidimensionally measurable site At
least 1.5 cm in its greatest dimension Not in field of prior radiotherapy Progressive
disease after at least one prior treatment regimen for lymphoma A new classification
scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of
"indolent" or "aggressive" lymphoma will replace the former terminology of "low",
"intermediate", or "high" grade lymphoma. However, this protocol uses the former
terminology.

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:
Not specified Hematopoietic: See Disease Characteristics Absolute neutrophil count at
least 1000/mm3 Platelet count at least 50,000/mm3 Hemoglobin at least 8 g/dL Hepatic:
Bilirubin no greater than 1.5 times upper limit of normal (ULN) ALT or AST no greater than
2 times ULN Albumin greater than 3.0 g/dL No hepatitis B or C infection Renal: Creatinine
no greater than ULN Other: Not pregnant or nursing Fertile patients must use effective
contraception HIV negative No active infection requiring anti-infective therapy No other
prior invasive malignancy within past 5 years, except: Curatively treated basal cell or
squamous cell skin cancer Carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY: Biologic therapy: Prior stem cell transplantation allowed At
least 4 weeks since prior biologic therapy No other concurrent immunotherapy Chemotherapy:
At least 4 weeks since prior chemotherapy No concurrent chemotherapy Endocrine therapy: At
least 4 weeks since prior endocrine therapy No concurrent hormonal therapy (except
contraceptives and replacement steroids) No concurrent corticosteroids Radiotherapy: See
Disease Characteristics At least 4 weeks since prior radiotherapy for localized disease No
concurrent radiotherapy Surgery: Not specified Other: No other concurrent experimental
medications (including approved drugs tested in an investigational setting)